DexCom, Inc. (NASDAQ:DXCM) Shares Acquired by MIG Capital LLC

MIG Capital LLC raised its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 51.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 859,627 shares of the medical device company’s stock after buying an additional 292,127 shares during the quarter. DexCom comprises 7.0% of MIG Capital LLC’s portfolio, making the stock its 6th largest position. MIG Capital LLC owned approximately 0.22% of DexCom worth $57,629,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Jennison Associates LLC raised its position in shares of DexCom by 1,683.2% during the 3rd quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the period. Legal & General Group Plc boosted its position in DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock valued at $339,352,000 after purchasing an additional 49,076 shares during the period. Westfield Capital Management Co. LP grew its stake in DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after buying an additional 876,739 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in DexCom by 11.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after buying an additional 288,381 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in DexCom by 16.9% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after buying an additional 353,019 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock valued at $399,319 over the last quarter. Company insiders own 0.30% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Oppenheimer lowered their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. upped their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Raymond James cut their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a report on Monday, August 5th. Finally, Piper Sandler restated an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Trading Up 0.2 %

NASDAQ DXCM opened at $78.10 on Thursday. The firm’s 50 day moving average price is $71.11 and its two-hundred day moving average price is $88.51. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $30.51 billion, a price-to-earnings ratio of 46.77, a PEG ratio of 2.38 and a beta of 1.17.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.